106 related articles for article (PubMed ID: 10217739)
1. Immediacy is both a liability and an asset of the Internet.
Huntley A
Dermatol Online J; 1997 Dec; 3(2):11b. PubMed ID: 10217739
[No Abstract] [Full Text] [Related]
2. Skin Cap: what have we learned, and when did we learn it?
Smith K
Dermatol Online J; 1997 Dec; 3(2):11c. PubMed ID: 10217740
[No Abstract] [Full Text] [Related]
3. Skin Cap and corticosteroids.
Boyce D
Dermatol Online J; 1997 Dec; 3(2):11e-11f. PubMed ID: 10328674
[No Abstract] [Full Text] [Related]
4. Skin Cap analysis in Spain.
Sanmartin O
Dermatol Online J; 1997 Dec; 3(2):11g. PubMed ID: 10328675
[No Abstract] [Full Text] [Related]
5. Editorial comment on Skin Cap.
Fleckman P
Dermatol Online J; 1997 Dec; 3(2):11a; discussion 11h. PubMed ID: 10328672
[No Abstract] [Full Text] [Related]
6. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of psoriasis treated with zinc pyrithione.
Aliaga A
Am J Dermatopathol; 2001 Apr; 23(2):161-2. PubMed ID: 11285418
[No Abstract] [Full Text] [Related]
8. [The "Antipsoriatic" Skin-Cap contains a non-declared potent corticosteroid].
Mrowietz U
Hautarzt; 1997 Dec; 48(12):947. PubMed ID: 9486372
[No Abstract] [Full Text] [Related]
9. Potent topical steroid in a Chinese herbal cream.
Wood B; Wishart J
N Z Med J; 1997 Nov; 110(1055):420-1. PubMed ID: 9418826
[TBL] [Abstract][Full Text] [Related]
10. Pustular psoriasis and hepatotoxicity associated with use of Skin Cap spray.
Tan JK
Dermatol Online J; 1997 Dec; 3(2):11d. PubMed ID: 10328673
[No Abstract] [Full Text] [Related]
11. Treatment of localized psoriasis with a topical formulation of zinc pyrithione.
Sadeghian G; Ziaei H; Nilforoushzadeh MA
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(4):187-90. PubMed ID: 22367374
[TBL] [Abstract][Full Text] [Related]
12. Cushing's syndrome from topical glucocorticoids.
Teelucksingh S; Bahall M; Coomansingh D; Suite M; Bartholomew C
West Indian Med J; 1993 Jun; 42(2):77-8. PubMed ID: 8367969
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical availability of clobetasol-17-propionate from cream and ointment.
Dyderski S; Grześkowiak E; Szałek E; Mrzygłód A
Acta Pol Pharm; 2001; 58(6):435-8. PubMed ID: 12197615
[TBL] [Abstract][Full Text] [Related]
14. The highly effective use of topical zinc pyrithione in the treatment of psoriasis: a case report.
Crutchfield CE; Lewis EJ; Zelickson BD
Dermatol Online J; 1997 Mar; 3(1):3. PubMed ID: 9141364
[TBL] [Abstract][Full Text] [Related]
15. Increased scalp skin lipids in response to antidandruff treatment containing zinc pyrithione.
Rogers JS; Moore AE; Meldrum H; Harding CR
Arch Dermatol Res; 2003 Jul; 295(3):127-9. PubMed ID: 12811576
[No Abstract] [Full Text] [Related]
16. Liquid chromatographic determination of clobetasone-17-butyrate in ointments.
Patel AG; Patel RB; Patel MR
J Assoc Off Anal Chem; 1990; 73(6):893-5. PubMed ID: 2289922
[TBL] [Abstract][Full Text] [Related]
17. Cushing's syndrome caused by topical steroid therapy for psoriasis.
Abma EM; Blanken R; De Heide LJ
Neth J Med; 2002 Apr; 60(3):148-50. PubMed ID: 12164372
[TBL] [Abstract][Full Text] [Related]
18. Histopathology of psoriasis treated with zinc pyrithione.
Rowlands CG; Danby FW
Am J Dermatopathol; 2000 Jun; 22(3):272-6. PubMed ID: 10871074
[TBL] [Abstract][Full Text] [Related]
19. Unregulated use of clobetasol propionate.
Keane FM; Munn SE; Taylor NF; du Vivier AW
Br J Dermatol; 2001 May; 144(5):1095-6. PubMed ID: 11359411
[No Abstract] [Full Text] [Related]
20. Psoriasis.
Blake J
Prof Nurse; 2002 Nov; 18(3):133-4. PubMed ID: 12465536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
